Neos Therapeutics Inc. (NEOS) Sees Large Increase in Short Interest
Neos Therapeutics Inc. (NASDAQ:NEOS) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 1,731,537 shares, a growth of 27.9% from the September 15th total of 1,353,962 shares. Based on an average daily volume of 205,683 shares, the days-to-cover ratio is presently 8.4 days. Currently, 19.9% of the shares of the company are short sold.
In related news, CFO Richard I. Eisenstadt purchased 3,710 shares of the business’s stock in a transaction dated Thursday, August 25th. The stock was acquired at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the completion of the purchase, the chief financial officer now directly owns 3,710 shares of the company’s stock, valued at $25,302.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.85% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of NEOS. ProShare Advisors LLC raised its position in shares of Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock valued at $126,000 after buying an additional 1,233 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Neos Therapeutics during the second quarter valued at approximately $200,000. Teachers Advisors Inc. raised its position in shares of Neos Therapeutics by 289.6% in the second quarter. Teachers Advisors Inc. now owns 21,924 shares of the company’s stock valued at $203,000 after buying an additional 16,296 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock valued at $267,000 after buying an additional 16,815 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock valued at $353,000 after buying an additional 16,046 shares during the last quarter. Institutional investors own 37.73% of the company’s stock.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 6.67 on Friday. Neos Therapeutics has a 12-month low of $6.33 and a 12-month high of $18.84. The firm’s market cap is $107.19 million. The firm has a 50-day moving average price of $7.05 and a 200 day moving average price of $8.63.
Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.49. The firm earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. On average, equities research analysts anticipate that Neos Therapeutics will post ($5.39) earnings per share for the current fiscal year.
A number of research analysts recently weighed in on NEOS shares. BMO Capital Markets started coverage on Neos Therapeutics in a report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price objective on the stock. Zacks Investment Research lowered Neos Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Five research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $20.94.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.